{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:36:56Z","timestamp":1777667816935,"version":"3.51.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T00:00:00Z","timestamp":1548720000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s40256-018-00315-3","type":"journal-article","created":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T01:47:54Z","timestamp":1548726474000},"page":"107-111","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["How Might Bromodomain and Extra-Terminal (BET) Inhibitors Operate in Cardiovascular Disease?"],"prefix":"10.1007","volume":"19","author":[{"given":"C. Mary","family":"Schooling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie V.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,29]]},"reference":[{"issue":"4","key":"315_CR1","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1517\/13543776.2016.1159299","volume":"26","author":"A Ghoshal","year":"2016","unstructured":"Ghoshal A, Yugandhar D, Srivastava AK. BET inhibitors in cancer therapeutics: a patent review. Expert Opin Ther Pat. 2016;26(4):505\u201322.","journal-title":"Expert Opin Ther Pat."},{"issue":"7504","key":"315_CR2","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/nature13229","volume":"510","author":"IA Asangani","year":"2014","unstructured":"Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature. 2014;510(7504):278\u201382.","journal-title":"Nature."},{"issue":"6","key":"315_CR3","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1248\/cpb.c16-00225","volume":"64","author":"T Noguchi-Yachide","year":"2016","unstructured":"Noguchi-Yachide T. BET bromodomain as a target of epigenetic therapy. Chem Pharm Bull (Tokyo). 2016;64(6):540\u20137.","journal-title":"Chem Pharm Bull (Tokyo)."},{"issue":"3","key":"315_CR4","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1177\/2040620715576662","volume":"6","author":"A Chaidos","year":"2015","unstructured":"Chaidos A, Caputo V, Karadimitris A. Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence. Ther Adv Hematol. 2015;6(3):128\u201341.","journal-title":"Ther Adv Hematol."},{"key":"315_CR5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.atherosclerosis.2016.01.036","volume":"247","author":"D Gilham","year":"2016","unstructured":"Gilham D, Wasiak S, Tsujikawa LM, Halliday C, Norek K, Patel RG, et al. RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I\/HDL and represses pathways that contribute to cardiovascular disease. Atherosclerosis. 2016;247:48\u201357.","journal-title":"Atherosclerosis."},{"issue":"4","key":"315_CR6","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s12265-017-9755-z","volume":"10","author":"S Wasiak","year":"2017","unstructured":"Wasiak S, Gilham D, Tsujikawa LM, Halliday C, Calosing C, Jahagirdar R, et al. Downregulation of the complement cascade in vitro, in mice and in patients with cardiovascular disease by the BET protein inhibitor apabetalone (RVX-208). J Cardiovasc Transl Res. 2017;10(4):337\u201347.","journal-title":"J Cardiovasc Transl Res."},{"key":"315_CR7","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aah5084","author":"Q Duan","year":"2017","unstructured":"Duan Q, McMahon S, Anand P, Shah H, Thomas S, Salunga HT, et al. BET bromodomain inhibition suppresses innate inflammatory and profibrotic transcriptional networks in heart failure. Sci Transl Med. 2017;9(390):eaah5084. \n                    https:\/\/doi.org\/10.1126\/scitranslmed.aah5084\n                    \n                  .","journal-title":"Sci Transl Med."},{"issue":"6","key":"315_CR8","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.metabol.2016.03.002","volume":"65","author":"AL Siebel","year":"2016","unstructured":"Siebel AL, Trinh SK, Formosa MF, Mundra PA, Natoli AK, Reddy-Luthmoodoo M, et al. Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes: a randomized controlled trial. Metabolism. 2016;65(6):904\u201314.","journal-title":"Metabolism."},{"issue":"2","key":"315_CR9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40256-017-0250-3","volume":"18","author":"SJ Nicholls","year":"2018","unstructured":"Nicholls SJ, Ray KK, Johansson JO, Gordon A, Sweeney M, Halliday C, et al. Selective BET protein inhibition with apabetalone and cardiovascular events: a pooled analysis of trials in patients with coronary artery disease. Am J Cardiovasc Drugs. 2018;18(2):109\u201315.","journal-title":"Am J Cardiovasc Drugs."},{"issue":"349","key":"315_CR10","doi-asserted-by":"publisher","first-page":"g4379","DOI":"10.1136\/bmj.g4379","volume":"18","author":"D Keene","year":"2014","unstructured":"Keene D, Price C, Shun-Shin MJ, Francis DP. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ. 2014;18(349):g4379.","journal-title":"BMJ."},{"issue":"23","key":"315_CR11","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1016\/j.jacc.2010.02.035","volume":"55","author":"D Bailey","year":"2010","unstructured":"Bailey D, Jahagirdar R, Gordon A, Hafiane A, Campbell S, Chatur S, et al. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J Am Coll Cardiol. 2010;55(23):2580\u20139.","journal-title":"J Am Coll Cardiol."},{"key":"315_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.phrs.2017.12.028","volume":"128","author":"N Ferri","year":"2018","unstructured":"Ferri N, Corsini A, Sirtori CR, Ruscica M. Present therapeutic role of cholesteryl ester transfer protein inhibitors. Pharmacol Res. 2018;128:29\u201341.","journal-title":"Pharmacol Res."},{"issue":"9","key":"315_CR13","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/eurheartj\/ehv213","volume":"37","author":"N Jackson","year":"2016","unstructured":"Jackson N, Atar D, Borentain M, Breithardt G, van Eickels M, Endres M, et al. Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology. Eur Heart J. 2016;37(9):747\u201354.","journal-title":"Eur Heart J."},{"issue":"9","key":"315_CR14","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/jamacardio.2018.2121","volume":"3","author":"SJ Nicholls","year":"2018","unstructured":"Nicholls SJ, Andrews J, Kastelein JJP, et al. Effect of serial infusions of CER-001, a pre-beta high-density lipoprotein mimetic, on coronary atherosclerosis in patients following acute coronary syndromes in the CER-001 atherosclerosis regression acute coronary syndrome trial: a randomized clinical trial. JAMA Cardiol. 2018;3(9):815\u201322.","journal-title":"JAMA Cardiol."},{"issue":"9","key":"315_CR15","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1001\/jamacardio.2018.2112","volume":"3","author":"SJ Nicholls","year":"2018","unstructured":"Nicholls SJ, Puri R, Ballantyne CM, et al. Effect of infusion of high-density lipoprotein mimetic containing recombinant apolipoprotein A-I Milano on coronary disease in patients with an acute coronary syndrome in the MILANO-PILOT trial: a randomized clinical trial. JAMA Cardiol. 2018;3(9):806\u201314.","journal-title":"JAMA Cardiol."},{"issue":"6","key":"315_CR16","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1001\/jamacardio.2016.1884","volume":"1","author":"J White","year":"2016","unstructured":"White J, Swerdlow DI, Preiss D, Fairhurst-Hunter Z, Keating BJ, Asselbergs FW, et al. Association of lipid fractions with risks for coronary artery disease and diabetes. JAMA Cardiol. 2016;1(6):692\u20139.","journal-title":"JAMA Cardiol."},{"issue":"4","key":"315_CR17","doi-asserted-by":"publisher","first-page":"e12265","DOI":"10.1111\/1755-5922.12265","volume":"35","author":"GC Ghosh","year":"2017","unstructured":"Ghosh GC, Bhadra R, Ghosh RK, Banerjee K, Gupta A. RVX 208: a novel BET protein inhibitor, role as an inducer of apo A-I\/HDL and beyond. Cardiovasc Ther. 2017;35(4):e12265.","journal-title":"Cardiovasc Ther."},{"issue":"22","key":"315_CR18","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1161\/CIRCULATIONAHA.108.814251","volume":"118","author":"PM Ridker","year":"2008","unstructured":"Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation. 2008;118(22):2243\u201351 (4p following 51).","journal-title":"Circulation."},{"issue":"2","key":"315_CR19","doi-asserted-by":"publisher","first-page":"695","DOI":"10.21037\/jtd.2018.01.119","volume":"10","author":"PL Thompson","year":"2018","unstructured":"Thompson PL, Nidorf SM. Anti-inflammatory therapy with canakinumab for atherosclerotic disease: lessons from the CANTOS trial. J Thorac Dis. 2018;10(2):695\u20138.","journal-title":"J Thorac Dis."},{"issue":"3","key":"315_CR20","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1001\/jama.2013.282836","volume":"311","author":"SJ Nicholls","year":"2014","unstructured":"Nicholls SJ, Kastelein JJ, Schwartz GG, Bash D, Rosenson RS, Cavender MA, et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA. 2014;311(3):252\u201362.","journal-title":"JAMA."},{"issue":"10","key":"315_CR21","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1001\/jama.2014.11061","volume":"312","author":"ML O\u2019Donoghue","year":"2014","unstructured":"O\u2019Donoghue ML, Braunwald E, White HD, Lukas MA, Tarka E, Steg PG, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA. 2014;312(10):1006\u201315.","journal-title":"JAMA."},{"issue":"18","key":"315_CR22","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1056\/NEJMoa1315878","volume":"370","author":"HD White","year":"2014","unstructured":"White HD, Held C, Stewart R, Tarka E, Brown R, Davies RY, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. 2014;370(18):1702\u201311.","journal-title":"N Engl J Med."},{"issue":"15","key":"315_CR23","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1001\/jama.2016.3609","volume":"315","author":"ML O\u2019Donoghue","year":"2016","unstructured":"O\u2019Donoghue ML, Glaser R, Cavender MA, Aylward PE, Bonaca MP, Budaj A, et al. Effect of losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial infarction: a randomized clinical trial. JAMA. 2016;315(15):1591\u20139.","journal-title":"JAMA."},{"key":"315_CR24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809798","author":"PM Ridker","year":"2018","unstructured":"Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2018. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1809798\n                    \n                  .","journal-title":"N Engl J Med."},{"issue":"27","key":"315_CR25","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1093\/eurheartj\/ehu203","volume":"35","author":"PM Ridker","year":"2014","unstructured":"Ridker PM, Luscher TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J. 2014;35(27):1782\u201391.","journal-title":"Eur Heart J."},{"issue":"12","key":"315_CR26","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119\u201331.","journal-title":"N Engl J Med."},{"issue":"4","key":"315_CR27","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrcardio.2017.161","volume":"15","author":"S Toldo","year":"2018","unstructured":"Toldo S, Abbate A. The NLRP3 inflammasome in acute myocardial infarction. Nat Rev Cardiol. 2018;15(4):203\u201314.","journal-title":"Nat Rev Cardiol."},{"issue":"9822","key":"315_CR28","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/S0140-6736(12)60110-X","volume":"379","author":"DI Swerdlow","year":"2012","unstructured":"Swerdlow DI, Holmes MV, Kuchenbaecker KB, Engmann JE, Shah T, Sofat R, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012;379(9822):1214\u201324.","journal-title":"Lancet."},{"issue":"10","key":"315_CR29","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrcardio.2017.78","volume":"14","author":"MV Holmes","year":"2017","unstructured":"Holmes MV, Ala-Korpela M, Smith GD. Mendelian randomization in cardiometabolic disease: challenges in evaluating causality. Nat Rev Cardiol. 2017;14(10):577\u201390.","journal-title":"Nat Rev Cardiol."},{"issue":"3","key":"315_CR30","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/CRD.0000000000000176","volume":"26","author":"B Tun","year":"2018","unstructured":"Tun B, Frishman WH. Effects of anti-inflammatory medications in patients with coronary artery disease: a focus on losmapimod. Cardiol Rev. 2018;26(3):152\u20136.","journal-title":"Cardiol Rev."},{"issue":"2","key":"315_CR31","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1701719","volume":"377","author":"S Jaiswal","year":"2017","unstructured":"Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377(2):111\u201321.","journal-title":"N Engl J Med."},{"issue":"1","key":"315_CR32","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1038\/s41467-018-05512-x","volume":"9","author":"C Yao","year":"2018","unstructured":"Yao C, Chen G, Song C, Keefe J, Mendelson M, Huan T, et al. Genome-wide mapping of plasma protein QTLs identifies putatively causal genes and pathways for cardiovascular disease. Nat Commun. 2018;9(1):3268.","journal-title":"Nat Commun."},{"issue":"10095","key":"315_CR33","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(16)31648-8","volume":"390","author":"CM Schooling","year":"2017","unstructured":"Schooling CM. Tachykinin neurokinin 3 receptor antagonists: a new treatment for cardiovascular disease? Lancet. 2017;390(10095):709\u201311.","journal-title":"Lancet."},{"issue":"6","key":"315_CR34","doi-asserted-by":"publisher","first-page":"e1006328","DOI":"10.1371\/journal.pgen.1006328","volume":"13","author":"SG Byars","year":"2017","unstructured":"Byars SG, Huang QQ, Gray LA, Bakshi A, Ripatti S, Abraham G, et al. Genetic loci associated with coronary artery disease harbor evidence of selection and antagonistic pleiotropy. PLoS Genet. 2017;13(6):e1006328.","journal-title":"PLoS Genet."},{"key":"315_CR35","doi-asserted-by":"publisher","unstructured":"Schooling CM, Ng J. Reproduction and longevity A Mendelian randomization study of gonadotropin-releasing hormone and ischemic heart disease. Biorxiv. 2018. \n                    https:\/\/doi.org\/10.1101\/472548\n                    \n                  .","DOI":"10.1101\/472548"},{"key":"315_CR36","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ijcard.2018.05.051","volume":"267","author":"CM Schooling","year":"2018","unstructured":"Schooling CM, Luo S, Au Yeung SL, Thompson DJ, Karthikeyan S, Bolton TR, et al. Genetic predictors of testosterone and their associations with cardiovascular disease and risk factors: a Mendelian randomization investigation. Int J Cardiol. 2018;267:171\u20136.","journal-title":"Int J Cardiol."},{"issue":"6","key":"315_CR37","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1210\/jc.2009-2575","volume":"95","author":"MM Fernandez-Balsells","year":"2010","unstructured":"Fernandez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(6):2560\u201375.","journal-title":"J Clin Endocrinol Metab."},{"key":"315_CR38","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.yhbeh.2016.11.017","volume":"88","author":"J Roved","year":"2017","unstructured":"Roved J, Westerdahl H, Hasselquist D. Sex differences in immune responses: Hormonal effects, antagonistic selection, and evolutionary consequences. Horm Behav. 2017;88:95\u2013105.","journal-title":"Horm Behav."},{"issue":"11","key":"315_CR39","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1161\/01.CIR.91.11.2742","volume":"91","author":"AA Ajayi","year":"1995","unstructured":"Ajayi AA, Mathur R, Halushka PV. Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses. Circulation. 1995;91(11):2742\u20137.","journal-title":"Circulation."},{"issue":"6","key":"315_CR40","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1067\/mpd.2003.246","volume":"142","author":"JA Morrison","year":"2003","unstructured":"Morrison JA, Barton BA, Biro FM, Sprecher DL. Sex hormones and the changes in adolescent male lipids: longitudinal studies in a biracial cohort. J Pediatr. 2003;142(6):637\u201342.","journal-title":"J Pediatr."},{"issue":"3","key":"315_CR41","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1136\/bjsm.2003.000199","volume":"38","author":"F Hartgens","year":"2004","unstructured":"Hartgens F, Rietjens G, Keizer HA, Kuipers H, Wolffenbuttel BH. Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). Br J Sports Med. 2004;38(3):253\u20139.","journal-title":"Br J Sports Med."},{"key":"315_CR42","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1741-7015-11-57","volume":"11","author":"CM Schooling","year":"2013","unstructured":"Schooling CM, Au Yeung SL, Freeman G, Cowling BJ. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC Med. 2013;11:57.","journal-title":"BMC Med."},{"issue":"13","key":"315_CR43","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1001\/jama.1973.03220410045010","volume":"225","author":"SS Stoffer","year":"1973","unstructured":"Stoffer SS, Hynes KM, Jiang NS, Ryan RJ. Digoxin and abnormal serum hormone levels. JAMA. 1973;225(13):1643\u20134.","journal-title":"JAMA."},{"issue":"1","key":"315_CR44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/humupd\/4.1.3","volume":"4","author":"M Rosselli","year":"1998","unstructured":"Rosselli M, Keller PJ, Dubey RK. Role of nitric oxide in the biology, physiology and pathophysiology of reproduction. Hum Reprod Update. 1998;4(1):3\u201324.","journal-title":"Hum Reprod Update."},{"issue":"8","key":"315_CR45","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1073\/pnas.1714478115","volume":"115","author":"S Palmer","year":"2018","unstructured":"Palmer S, Albergante L, Blackburn CC, Newman TJ. Thymic involution and rising disease incidence with age. Proc Natl Acad Sci USA. 2018;115(8):1883\u20138.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"19","key":"315_CR46","doi-asserted-by":"publisher","first-page":"E4316","DOI":"10.1073\/pnas.1802584115","volume":"115","author":"CM Schooling","year":"2018","unstructured":"Schooling CM, Zhao JV. Strengthening the immune system for cancer prevention. Proc Natl Acad Sci USA. 2018;115(19):E4316\u20137.","journal-title":"Proc Natl Acad Sci USA."},{"key":"315_CR47","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/bs.acr.2016.04.001","volume":"131","author":"CA French","year":"2016","unstructured":"French CA. Small-molecule targeting of BET proteins in cancer. Adv Cancer Res. 2016;131:21\u201358.","journal-title":"Adv Cancer Res."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-018-00315-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-018-00315-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-018-00315-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T00:13:06Z","timestamp":1580256786000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-018-00315-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,29]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["315"],"URL":"https:\/\/doi.org\/10.1007\/s40256-018-00315-3","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,29]]},"assertion":[{"value":"29 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}